• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Progress in Pharmacotherapy for Obesity.肥胖症药物治疗的进展
JAMA. 2021 Jul 13;326(2):129-130. doi: 10.1001/jama.2021.9486.
2
At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.在肥胖症周期间，关于司美格鲁肽、替尔泊肽和瑞替鲁肽有更多数据及问题。
JAMA. 2024 Jan 2;331(1):9-11. doi: 10.1001/jama.2023.23141.
3
Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management.表：用于慢性体重管理的胰高血糖素样肽-1及葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-e2. doi: 10.58347/tml.2024.1708d.
4
Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?为何在无2型糖尿病的肥胖成年人中，胰高糖素样肽-1（GLP-1）激动剂联合葡萄糖依赖性促胰岛素多肽（GIP）和/或胰高血糖素原（GCG）激动剂比单独使用GLP-1激动剂具有更强的减重效果？
Diabetes Obes Metab. 2025 Mar;27(3):1079-1095. doi: 10.1111/dom.16106. Epub 2024 Nov 26.
5
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
6
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.关于新型基于胰高血糖素样肽-1受体激动剂（GLP-1RA）的减肥疗法的使用、临床及对比疗效和不良反应的真实世界证据。
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.
7
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.胰高血糖素样肽-1受体激动剂在无糖尿病成年人中减肥的疗效和安全性：随机对照试验的系统评价
Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7.
8
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.基于肠促胰岛素的强效肥胖治疗：司美格鲁肽和替尔泊肽对体重和腰围影响及安全性的系统评价与荟萃分析
Obes Rev. 2024 May;25(5):e13717. doi: 10.1111/obr.13717. Epub 2024 Mar 11.
9
Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study.数字参与对使用GLP-1和双重GLP-1/GIP受体激动剂疗法的肥胖症患者体重减轻结果的影响：回顾性队列服务评估研究。
J Med Internet Res. 2025 Mar 31;27:e69466. doi: 10.2196/69466.
10
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.用于2型糖尿病、肥胖症及相关合并症治疗的多功能肠促胰岛素肽
Peptides. 2025 May;187:171380. doi: 10.1016/j.peptides.2025.171380. Epub 2025 Mar 11.

引用本文的文献

1
Correlation of the differential expressions of RANK, RANKL, and OPG with obesity in the elderly population in Xinjiang.新疆老年人群中RANK、RANKL和OPG的差异表达与肥胖的相关性
Open Med (Wars). 2025 Aug 7;20(1):20251196. doi: 10.1515/med-2025-1196. eCollection 2025.
2
Patterns and predictors of self-medication behavior of weight loss medications: a cross-sectional analysis of social media influence and role of pharmacist intervention.减肥药物自我用药行为的模式及预测因素：社交媒体影响与药剂师干预作用的横断面分析
Front Pharmacol. 2025 Jul 14;16:1606566. doi: 10.3389/fphar.2025.1606566. eCollection 2025.
3
Calcium/Calmodulin-Dependent Protein Kinase II Inhibitors Mitigate High-Fat Diet-Induced Obesity in Mice.钙/钙调蛋白依赖性蛋白激酶II抑制剂减轻高脂饮食诱导的小鼠肥胖。
J Obes. 2025 Jun 30;2025:5530467. doi: 10.1155/jobe/5530467. eCollection 2025.
4
Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.减肥药物与代谢相关脂肪性肝病：在resmetirom之前对肝病学和胃肠病学医疗服务提供者的实践、态度及知识的全国性调查
J Clin Gastroenterol. 2025 Jun 23. doi: 10.1097/MCG.0000000000002147.
5
Transdermal microneedle patches as a promising drug delivery system for anti-obesogenic molecules.透皮微针贴片作为一种用于抗肥胖分子的有前景的药物递送系统。
Front Bioeng Biotechnol. 2024 Jun 11;12:1380537. doi: 10.3389/fbioe.2024.1380537. eCollection 2024.
6
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.每周一次替西帕肽用于体重管理的疗效和安全性与安慰剂相比：一项包括最新 SURMOUNT-2 试验的更新系统评价和荟萃分析。
Endocrine. 2024 Oct;86(1):70-84. doi: 10.1007/s12020-024-03896-z. Epub 2024 Jun 8.
7
Single high-dose intravenous injection of Wharton's jelly-derived mesenchymal stem cell exerts protective effects in a rat model of metabolic syndrome.单次大剂量静脉注射牙髓间充质干细胞在代谢综合征大鼠模型中发挥保护作用。
Stem Cell Res Ther. 2024 Jun 5;15(1):160. doi: 10.1186/s13287-024-03769-2.
8
Unraveling the Variability of Human Satiation: Implications for Precision Obesity Management.解析人类饱腹感的变异性：对精准肥胖管理的启示。
Res Sq. 2024 May 23:rs.3.rs-4402499. doi: 10.21203/rs.3.rs-4402499/v1.
9
Critical Correlation Between Obesity and Cardiovascular Diseases and Recent Advancements in Obesity.肥胖与心血管疾病的关键关联及肥胖领域的最新进展
Cureus. 2024 Jan 4;16(1):e51681. doi: 10.7759/cureus.51681. eCollection 2024 Jan.
10
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities.生活方式改变与第二代抗肥胖药物的作用：比较、问题与临床机遇。
Curr Obes Rep. 2023 Dec;12(4):453-473. doi: 10.1007/s13679-023-00534-z. Epub 2023 Dec 2.

本文引用的文献

1
Once-Weekly Semaglutide in Adults with Overweight or Obesity. Reply.超重或肥胖成人的每周一次司美格鲁肽。回复。
N Engl J Med. 2021 Jul 1;385(1):e4. doi: 10.1056/NEJMc2106918.
2
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.持续每周皮下注射司美格鲁肽与安慰剂对超重或肥胖成年人体重维持的影响：STEP 4 随机临床试验。
JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
3
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.司美格鲁肽 2·4 毫克每周一次治疗超重或肥胖、以及 2 型糖尿病成人患者（STEP 2）：一项随机、双盲、双模拟、安慰剂对照、3 期临床试验。
Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2.
4
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.皮下司美格鲁肽与安慰剂作为强化行为疗法辅助手段对超重或肥胖成人体重的影响：STEP 3 随机临床试验。
JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831.
5
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.替尔泊肽（双重GIP和GLP-1受体激动剂）在2型糖尿病管理中的作用：SURPASS临床试验
Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15.
6
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.利拉鲁肽治疗肥胖青少年的随机对照试验。
N Engl J Med. 2020 May 28;382(22):2117-2128. doi: 10.1056/NEJMoa1916038. Epub 2020 Mar 31.
7
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.利拉鲁肽 3.0 毫克治疗合并 2 型糖尿病的超重或肥胖患者的疗效和安全性：SCALE 胰岛素随机对照试验。
Diabetes Care. 2020 May;43(5):1085-1093. doi: 10.2337/dc19-1745. Epub 2020 Mar 5.
8
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.肥胖症药物治疗与体重减轻及不良事件的关联：一项系统评价与荟萃分析。
JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602.
9
Naltrexone extended-release plus bupropion extended-release for treatment of obesity.纳曲酮缓释剂加安非他酮缓释剂用于治疗肥胖症。
JAMA. 2015;313(12):1213-4. doi: 10.1001/jama.2015.1617.
10
Long-term drug treatment for obesity: a systematic and clinical review.长期药物治疗肥胖：系统评价和临床综述。
JAMA. 2014 Jan 1;311(1):74-86. doi: 10.1001/jama.2013.281361.

Progress in Pharmacotherapy for Obesity.

作者信息

Yanovski Susan Z, Yanovski Jack A

机构信息

Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.

Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

出版信息

JAMA. 2021 Jul 13;326(2):129-130. doi: 10.1001/jama.2021.9486.

DOI:10.1001/jama.2021.9486
PMID:34160571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8277731/
Abstract
摘要